{"product_id":"bcrx-bcg-matrix","title":"(BCRX) BioCryst Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BioCryst Pharmaceuticals, Inc. BCG Matrix is a company-specific analysis used to see how its products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the report content, so you can review the format and depth before buying. Purchase the full version to get the complete ready-to-use analysis instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORLADEYO HAE franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORLADEYO is BioCryst Pharmaceuticals, Inc.’s lead marketed product for hereditary angioedema prophylaxis, and it remains the clearest Star in the BCG Matrix: high share, high growth, and still the main commercial engine. As an oral small-molecule therapy, it has broad use potential versus injectable rivals, which supports durable demand. In BioCryst Pharmaceuticals, Inc.’s 2025 results, ORLADEYO continued to drive most product revenue and portfolio value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORLADEYO U.S. sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.'s U.S. ORLADEYO sales are the core growth engine, since the U.S. is the largest market for its only major revenue brand. As a once-daily oral therapy for hereditary angioedema, ORLADEYO keeps gaining uptake in a specialty market where convenience matters, and that supports star status. Continued U.S. demand is the key watch item for 2025 results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORLADEYO multi-region approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORLADEYO is approved and commercialized in the U.S., EU, UK, and Japan, giving BioCryst Pharmaceuticals, Inc. a multi-region footprint for hereditary angioedema. That wider reach expands the treatable patient pool beyond one market and lengthens the franchise runway. This is what a Star looks like: strong growth potential plus geographic expansion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eORLADEYO oral once-daily profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORLADEYO's oral once-daily dosing is a clear edge in hereditary angioedema (HAE) prophylaxis, where many rivals are injectable. BioCryst reported ORLADEYO net revenue of 166.8 million in Q1 2025, up 22% year over year, showing the pill form is still helping win share in a growing niche.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnce-daily oral use improves convenience\u003c\/li\u003e\n\u003cli\u003eStandout vs injectable HAE prophylaxis\u003c\/li\u003e\n\u003cli\u003eQ1 2025 revenue: 166.8 million\u003c\/li\u003e\n\u003cli\u003eYear-over-year growth: 22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eORLADEYO revenue concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn BioCryst Pharmaceuticals, Inc.'s 2025 mix, ORLADEYO still drove almost all product sales, so the company's growth, margin, and cash flow depend heavily on one brand. That kind of concentration is risky, but it also fits a Star in the BCG Matrix because ORLADEYO still has high expansion potential in hereditary angioedema.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 revenue stayed highly concentrated\u003c\/li\u003e\n\u003cli\u003eORLADEYO carried most growth expectations\u003c\/li\u003e\n\u003cli\u003eHigh share plus expansion = Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORLADEYO Drives BioCryst’s Growth With 22% Q1 Revenue Jump\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORLADEYO is BioCryst Pharmaceuticals, Inc.'s Star: it held 166.8 million of net revenue in Q1 2025, up 22% year over year, and still drove nearly all product sales. Its once-daily oral dosing and approvals in the U.S., EU, UK, and Japan support continued share gains in hereditary angioedema.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 net revenue\u003c\/td\u003e\n\u003ctd\u003e166.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003eU.S., EU, UK, Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBioCryst’s BCG Matrix likely centers on Orladeyo as a Star\/Cash Cow, with pipeline assets as Question Marks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean, quadrant-based BioCryst Pharmaceuticals BCG Matrix that clarifies portfolio pain points fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for BioCryst Pharmaceuticals, Inc., boosting credibility and helping decision-makers verify key claims fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTorii Pharmaceutical Japan license\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. Japan license with Torii Pharmaceutical is a classic cash cow: a mature local partnership that can bring in royalties with little direct selling spend. In 2025, this kind of asset helps BioCryst offset R\u0026amp;D-heavy cash use while keeping Japan exposure in place. If Torii keeps Orladeyo uptake steady, the stream stays low-risk and margin-rich.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeqirus UK partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeqirus UK Limited is a named BioCryst collaborator, and this kind of licensing tie-up usually fits a cash cow slot: low capital needs, steady contract cash, and limited expansion spend. BioCryst does not break out Seqirus UK revenue separately in its public filings, so the partnership is best read as a recurring cash-support line rather than a growth engine. That makes it useful for funding core programs without heavy new investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShionogi influenza agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. has been a BioCryst Pharmaceuticals, Inc. partner in Japan for years, and the deal is built on mature regional commercialization rather than early-stage R\u0026amp;D. In a BCG Matrix, that makes it closer to a cash cow: steady, recurring income with low reinvestment needs. It is the kind of long-running agreement that can keep cash flowing even when growth is limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGreen Cross Korea collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGreen Cross Korea is a classic Cash Cow for BioCryst: an established regional partner can keep generating royalty-like cash with limited new selling spend. Mature rights in Korea and nearby markets usually carry high incremental margins, so even modest sales can support steady profit. That fits BioCryst’s 2025-style portfolio logic: low capex, low promotion, recurring cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished partner, lower commercial spend\u003c\/li\u003e\n\u003cli\u003eRecurring cash, margin-friendly economics\u003c\/li\u003e\n\u003cli\u003eMature rights fit Cash Cow profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMundipharma territory rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMundipharma International Holdings Limited is one of BioCryst Pharmaceuticals, Inc.'s collaboration assets, and its territory rights fit the Cash Cows bucket because these deals can deliver steady, low-growth royalty income. That cash helps fund R and D and supports liquidity while BioCryst scales Orladeyo, which drove most of the Company's 2025 revenue mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady royalty-style cash\u003c\/li\u003e\n\u003cli\u003eLow capital needs\u003c\/li\u003e\n\u003cli\u003eSupports R and D funding\u003c\/li\u003e\n\u003cli\u003eBacks the balance sheet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Cash Cows: Royalty Deals Funding Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.’s Cash Cows are its mature licensing links with Torii Pharmaceutical, Shionogi \u0026amp; Co., Ltd., Green Cross Korea, Mundipharma International Holdings Limited, and Seqirus UK Limited. These deals are low-capex and royalty-like, so they help fund R and D while BioCryst’s 2025 sales were still led by Orladeyo.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTorii\u003c\/td\u003e\n\u003ctd\u003eJapan royalties\u003c\/td\u003e\n\u003ctd\u003eSteady\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShionogi\u003c\/td\u003e\n\u003ctd\u003eMature rights\u003c\/td\u003e\n\u003ctd\u003eRecurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eBioCryst Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact BioCryst Pharmaceuticals, Inc. BCG Matrix report you’ll receive after purchase. The full document is the same professionally formatted file—no demo pages, no watermarks, no placeholders. Once purchased, it’s ready to download, use, and present immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAPIVAB peramivir injection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAPIVAB (peramivir injection) is BioCryst Pharmaceuticals, Inc.'s IV antiviral for acute uncomplicated influenza, but influenza antivirals sit in a mature, seasonal market. BioCryst's 2025 filings do not show meaningful RAPIVAB revenue, which points to low share and weak growth, fitting a Dog in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAPIACTA peramivir brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAPIACTA is BioCryst Pharmaceuticals, Inc.’s brand for peramivir, an IV flu drug used in a narrow acute-care setting. The market is highly seasonal, tied to winter flu spikes, so demand is uneven and hard to scale. That limits revenue upside and keeps RAPIACTA in dog territory within the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePERAMIFLU peramivir brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePERAMIFLU (peramivir) sits in BioCryst Pharmaceuticals, Inc.'s mature neuraminidase inhibitor niche, so it fits a Dogs profile with low growth and limited strategic lift. BioCryst has not flagged it as a major 2025–2026 revenue driver, while the company's growth story stays centered on ORLADEYO.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcute uncomplicated influenza niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePeramivir is approved for acute uncomplicated influenza, a short-duration, crowded antiviral niche with limited pricing power and little room to expand beyond seasonal demand. That fits the dog quadrant for BioCryst Pharmaceuticals, Inc.: the flu market is dominated by broader, cheaper oral and nasal options, while BioCryst’s HAE franchise and pipeline offer far stronger growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcute, seasonal use only\u003c\/li\u003e\n\u003cli\u003eSmall share vs HAE growth\u003c\/li\u003e\n\u003cli\u003eLimited expansion potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy neuraminidase inhibitor franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.’s legacy neuraminidase inhibitor franchise is a Dog in its BCG Matrix: peramivir is an older influenza antiviral with little long-term growth upside, while newer flu assets have been largely eclipsed by better therapies and seasonal demand swings.\u003c\/p\u003e\n\u003cp\u003eThe franchise sits far behind ORLADEYO, which drove most of BioCryst Pharmaceuticals, Inc.’s business and reported 2025 net revenue of about $0.0B from this legacy class, versus much stronger growth from newer programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePeramivir is a legacy antiviral asset.\u003c\/li\u003e\n\u003cli\u003eInfluenza drugs face weak growth.\u003c\/li\u003e\n\u003cli\u003eBioCryst Pharmaceuticals, Inc. should prioritize ORLADEYO.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Legacy Flu Assets: A Classic Dog\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.’s peramivir-based flu assets are Dogs: a mature, seasonal antiviral niche with little growth and weak share. In BioCryst Pharmaceuticals, Inc.’s 2025 filings, this legacy class contributed about $0.0B in net revenue, while ORLADEYO drove the growth story.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eBioCryst Pharmaceuticals, Inc.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 net revenue\u003c\/td\u003e\n\u003ctd\u003eabout $0.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003eseasonal flu antivirals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG fit\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCX9930 Phase II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBCX9930 is BioCryst Pharmaceuticals, Inc.'s oral factor D inhibitor, still in Phase II, so it fits the BCG Matrix \"Question Mark\" bucket. It targets complement-mediated diseases, but it has 0 commercial share and no product revenue yet. Its value still depends on late-stage clinical data and a clear path to approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCX9250 Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBCX9250 is BioCryst Pharmaceuticals, Inc.’s oral ALK-2 inhibitor in Phase I for fibrodysplasia ossificans progressiva, a rare disease affecting about 1 in 2 million people. That early-stage profile makes it a classic Question Mark in the BCG matrix: high upside, but no proven clinical or commercial fit yet. Its value will depend on Phase I safety and target engagement data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalidesivir Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalidesivir sits in the Question Marks bucket: it is a Phase I RNA dependent-RNA polymerase inhibitor studied against four RNA viruses, Marburg, Yellow Fever, Ebola, and Zika. The broad antiviral idea is attractive, but BioCryst Pharmaceuticals, Inc. has not shown clear market traction or late-stage proof yet, so its commercial payoff remains uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eComplement-mediated diseases pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.'s complement-mediated diseases pipeline is still a Question Mark because it rests mainly on BCX9930, a high-interest oral complement C5 inhibitor in a field with clear growth room. The program can gain share only if it keeps producing strong clinical data and secures more capital to fund larger trials and commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBCX9930 is the core asset\u003c\/li\u003e\n\u003cli\u003eComplement biology has growth room\u003c\/li\u003e\n\u003cli\u003eData and capital drive conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFibrodysplasia ossificans progressiva program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBCX9250 targets fibrodysplasia ossificans progressiva, a disease seen in about 1 in 2 million people worldwide, so even small proof-of-concept gains can matter. The unmet need is high because FOP causes progressive bone formation in soft tissue and has no cure. Until BioCryst Pharmaceuticals, Inc. shows clearer efficacy and safety data, the program stays a question mark. Rare-disease pricing can be strong, but the market is tiny.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease, high unmet need.\u003c\/li\u003e\n\u003cli\u003eSmall market, strong pricing power.\u003c\/li\u003e\n\u003cli\u003eProof of concept still needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Early-Stage Bets: Big Upside, High Execution Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.’s Question Marks are BCX9930, BCX9250, and galidesivir: all are early-stage assets with no product revenue and no proven market share yet. BCX9930 is the lead program in Phase II, while BCX9250 and galidesivir are still in Phase I, so each needs strong data to move out of the Question Mark box. The upside is real, but so is the execution risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eWhy it is a Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCX9930\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eNo sales, data still needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCX9250\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eVery early, no proof yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalidesivir\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eBroad antiviral idea, no traction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234090328329,"sku":"bcrx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bcrx-bcg-matrix.webp?v=1785712695","url":"https:\/\/dcfanalyst.com\/products\/bcrx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}